title: TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
abstract: OBJECTIVE
  We investigated the relevance of donor bone marrow cell infusion (DBMI) and serum levels of interferon-gamma (IFN-gamma), interleukin-10 (IL-10), and soluble CD30 (sCD30) in kidney recipients.
  
  
  METHODS
  We analyzed the allograft outcomes correlated with sCD30, IFN-gamma, and IL-10 levels using pre- and posttransplantation sera from 40 live donor renal transplants (20 patients with DBMI [2.1 x 10(9) +/- 1.3 x 10(9) mononuclear cells/body] and 20 controls).
  
  
  RESULTS
  Patients with acute rejection episodes (ARE)-3/20 DBMI and 6/20 controls-showed increased sCD30 and IFN-gamma as well as decreased IL-10 posttransplantation compared with nonrejectors. Significant differences were observed for sCD30 and IFN-gamma levels: 59.54 vs 30.92 ng/mL (P = .02) and 11.91 vs 3.01 pg/mL (P = .01), respectively. Comparison of pre- and posttransplant levels of IFN-gamma, IL-10, and sCD30 in ARE patients showed higher levels in posttransplant sera except for IFN-gamma in controls (6.37 vs 11.93; P = .01). Increased IFN-gamma and IL-10 were correlated with rejection (r = .93; P = .008). sCD30 correlated with serum creatinine among ARE patients in control and DBMI groups (r = .89; P = .019; and r = 1.00; P < .0001, respectively).
  
  
  CONCLUSIONS
  Higher levels of sCD30, IFN-gamma, and IL-10 posttransplantation in rejecting patients provided evidence for coexistence of cellular and humoral responses in ARE. There appeared to be a down-regulatory effect of infusion on alloresponses.
authors.affiliation: Molecular Immunology Research Center, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: G
authors.initials: G
authors.lastname: Solgi
authors.forename: A A
authors.initials: AA
authors.lastname: Amirzagar
authors.forename: G
authors.initials: G
authors.lastname: Pourmand
authors.forename: A R
authors.initials: AR
authors.lastname: Mehrsai
authors.forename: M
authors.initials: M
authors.lastname: Taherimahmoudi
authors.forename: N
authors.initials: N
authors.lastname: Baradaran
authors.forename: M H
authors.initials: MH
authors.lastname: Nicknam
authors.forename: M R
authors.initials: MR
authors.lastname: Ebrahimi Rad
authors.forename: A
authors.initials: A
authors.lastname: Saraji
authors.forename: A A
authors.initials: AA
authors.lastname: Asadpoor
authors.forename: M
authors.initials: M
authors.lastname: Moheiydin
authors.forename: B
authors.initials: B
authors.lastname: Nikbin
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood; D016026:Bone Marrow Transplantation / Q000276:immunology*; D016207:Cytokines / Q000097:blood*; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D015234:HLA-A Antigens / Q000097:blood; D015235:HLA-B Antigens / Q000097:blood; D006684:HLA-DR Antigens / Q000097:blood; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D017730:Ki-1 Antigen / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors / Q000706:statistics & numerical data; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D015703:Antigens, CD; D016207:Cytokines; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D017730:Ki-1 Antigen; D016753:Interleukin-10; D007371:Interferon-gamma